MedTrace Logo

Accelerated Non-Atherosclerotic Brain Arterial Aging Relationship to Alzheimer's Disease

NCT04510168 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 238

Last updated 2024-07-16

No results posted yet for this study

Summary

The aging of the United States (US) population will lead to a steep rise in Alzheimer disease (AD). There is an urgent need for novel therapies that may tackle this looming societal problem. People with Alzheimer disease have frequently evidence of vascular disease in the brain, and vascular disease can increase the risk of Alzheimer disease. Based on this finding, the investigators plan to expand the understanding of how vascular disease contributes to Alzheimer disease, hoping to identify novel target to modify the natural progression of the disease. The investigators will accomplish this goal by inviting 300 participants (with and without dementia) of the Northern Manhattan Study (NOMAS) to undergo a brain magnetic resonance imaging (MRI) and donate blood. Of the 300 participants enrolled, 60 participants will be randomly selected to undergo Aβ and tau positron emission tomography (PET) imaging.

From the brain MRI, the investigators will obtain measurements of cerebrovascular disease and relate the to the risk of Alzheimer disease. With the blood, the investigators hope to identify measures of aging and inflammation that may predict changes noted in brain scan and identify people at a higher risk of dementia. The investigators will examine PET markers of inflammation and aging in the brain and how the markers relate to dementia.

Conditions

Interventions

DRUG

11C-ER176

PET imaging to measure 18kDa translocator protein; target imaging dose of up to 20 millicurie (mCi)

DRUG

[F-18]MK-6240

PET imaging to measure tau; target imaging dose of 4 to 5 mCi

DRUG

Florbetaben

PET radioligand that binds to amyloid plaques; target-imaging dose of up to 8.1 mCi

OTHER

Magnetic Resonance Imaging

Brain MRI

Sponsors & Collaborators

  • Jose Gutierrez, MD, MPH

    lead OTHER

Principal Investigators

  • Jose Gutierrez, MD, MPH · Columbia University

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-09-18
Primary Completion
2024-04-16
Completion
2024-04-17
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04510168 on ClinicalTrials.gov